Answers are grounded in this paper and cite their sources.
The current pandemic of COVID-19 is considered a worldwide threat to public health causedby a novel type of coronaviridae family called SARS-CoV-2. Owing to the urge of finding atreatment for this virulent virus, many aspects of drug development are swept aside. Thisreview aimed to clarify the double-edged sword of drug repurposing in COVID-19 viasummarizing the available treatment options and promising candidates for COVID-19 basedon drug repurposing preclinical studies and in-silico approach. Different drugs target SARSCoV-2 main structures under clinical investigation; some showed limited efficacy and severeside effects, while others can be promising solutions. Some drugs suppress the cytokine stormand modulate immune response during viral infection, including anti-interleukin andglucocorticoids. Antiparasitic agents are repurposed for SARS-CoV-2 infection management.Various vaccines and monoclonal antibodies are designed against SARS-CoV-2 and are beingevaluated in different preclinical and clinical stages. However, none of them is approved yet.Convalescent Plasma Transfusion is a promising strategy against SARS-CoV-2 infection,where impressive results are reported in clinical trials, requiring more validation. Furthermore,anticoagulant therapy exhibited better disease outcomes in patients admitted to the ICU.Finally, in-silico studies suggested several potential compounds or FDA-approved drugstargeting various viral structure subunits. In conclusion, although many clinical trials werelaunched to examine potential therapies based on drug repurposing for COVID-19, there is nodefinitive treatment till now. Moreover, computational approaches identified severalcompounds and FDA-approved drugs with potential inhibitory effects.
No takes yet. Share an insight, caveat, or question.
Abdelgawad et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: